Nuvilex Inc. (NASDAQ:PMCB – Get Free Report) saw a significant growth in short interest in September. As of September 30th, there was short interest totaling 133,885 shares, a growth of 90.1% from the September 15th total of 70,436 shares. Currently, 1.4% of the shares of the company are short sold. Based on an average daily volume of 533,557 shares, the short-interest ratio is presently 0.3 days.
Nuvilex Stock Performance
Shares of PMCB traded down $0.02 during mid-day trading on Friday, reaching $0.34. The stock had a trading volume of 32,984 shares, compared to its average volume of 200,380. The firm has a market cap of $3.65 million, a price-to-earnings ratio of -0.15 and a beta of 0.68. Nuvilex has a 12 month low of $0.33 and a 12 month high of $1.51. The business has a fifty day moving average of $0.46 and a 200 day moving average of $0.63.
Nuvilex (NASDAQ:PMCB – Get Free Report) last announced its quarterly earnings data on Monday, September 14th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.48).
Analyst Ratings Changes
Separately, Weiss Ratings cut Nuvilex from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 2nd. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company presently has a consensus rating of “Sell”.
Check Out Our Latest Stock Analysis on PMCB
About Nuvilex
Nuvilex, Inc was a biotechnology company that developed therapies for cancer and other serious diseases. The company focused on combining cellular therapy with drug-delivery technologies intended to provide localized treatment while limiting exposure to healthy tissue.
Its principal program involved the Cell-in-a-Box technology, which uses encapsulated genetically engineered cells to convert certain chemotherapy prodrugs into active cancer-fighting compounds at or near a tumor. Nuvilex applied this approach primarily to pancreatic cancer, including a planned treatment regimen involving encapsulated cells and ifosfamide.
Nuvilex later changed its name to PharmaCyte Biotech, Inc and continued development of the Cell-in-a-Box platform under the PharmaCyte Biotech name.
Recommended Stories
- Five stocks we like better than Nuvilex
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Nuvilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvilex and related companies with MarketBeat.com's FREE daily email newsletter.
